French biotech CellProthera welcomes three exceptional talents to its executive management team
CellProthera SAS, a clinical stage biotechnology company developing a novel cell therapy for the regeneration of damaged heart tissue and other impaired organs, has strengthened its executive management team to foster the development of its main clinical program and extend it to new therapeutic indications.
Ibon Garitaonandia is appointed Chief Scientific Officer (CSO). His extensive experience in drug discovery and in the development of novel stem cell products will accelerate the translation of CellProthera’s cell therapy platform into new treatments for regenerative medicine. He has 15 years’ experience in stem cell research and regenerative medicine, and has worked at the Richmond Research Institute in London, Histocell in Spain and International StemCell Corporation in California, the firstcompany to receive global regulatory approval to conduct a human pluripotent stem cell-based clinical trial for Parkinson’s disease.
Henk Streefkerk, MD PhD, takes the role of Chief Medical Officer (CMO). He brings decades of leadership in clinical research to boost the strategic development of the company and advance its pipeline of novel therapeutic solutions. After graduating from the University Medical Center Utrecht, Henk worked as Clinical Pharmacologist for Organon/Schering-Plough in the Netherlands. He then joined Actelion in Switzerland before taking the positions of Translational Medicine Expert and later Senior Brand Safety Leader with Novartis in Basel. After Novartis, he worked as Medical Director and Chief Medical Officer of a biotech specialized in oncology in Basel.
Olivier Friedrich is appointed Chief Financial Officer (CFO). His solid history of helping companies and start-ups to scale up in their development journey is key for CellProthera as it enters its next stage of development. A lecturer at EM Strasbourg in Finance and Regulation, Olivier brings 15 years of experience in corporate finance, internal control, accounting and tax matters. He held leadership positions with Ernst & Young for more than 10 years, leading financial audits and due diligence transactions for a wide spectrum of industrial firms and as CFO, supporting the cash and financing management of listed companies in the energy and car industry.
“The arrival of these three talents - all experts in their field - in the executive management team is a great boost to our ambitious, multi-indications development program and position us ideally to accelerate our pathway to market.", stated Matthieu de Kalbermatten, Chairman of CellProthera. “The wealth of their international experience will be useful to shape and steer the company effectively during the next clinical and regulatory stages.”
CellProthera developsa medical innovation that enables a heart damaged by a heart attack to regenerate by injecting stem cells originated from the patient's own blood.
As such, each patient becomes his own source of medicine!
The stem cell product ProtheraCytes® is obtained from a proprietary technology developed by CellProthera. It is injected into the heart tissue to be regenerated. In a few months, the heart muscle will regain its functionality, thus avoiding future treatments that are often severe, and in some cases, the need for a heart transplant.
Contact us! www.cellprothera.com/fr/
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Press contact: Mediatiser – Antoine Monnier / email@example.com
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TMD Security Launches Next Generation Key-less Lock Solutions for ATM Safe, Top Box and Access Doors30.11.2021 07:00:00 CET | Press release
TMD Security, global leader in high security ATM and branch access management, announced today the launch of its in-house R&D developed intelligent lock solutions for all types of access points. TMD key-less lock solutions for ATMs and access doors are integrated into TMD High Security Access Management which centrally manages all users and locations with one process and a real-time audit trail. Access for service engineers, branch staff and Cash-in-Transit (CIT) teams is scheduled and pre-approved. At the time of access, user and lock credentials are instantly checked and if correct, an encrypted One Time Code (OTC) is sent directly to the lock via the mobile app. TMD ATM safe lock is unique because the security and intelligence are inside the Lock Controller, located inside the safe behind the door. The OTC is sent directly to the Lock Controller via the mobile app. With no need for a keypad, the Lock Controller is an ‘invisible’ lock for the safe or access door. TMD’s user-friendly
Vifor Pharma announces changes to the Executive Committee as CFO retires30.11.2021 07:00:00 CET | Press release
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced that Colin Bond, Chief Financial Officer will retire from the company by the end of December 2021 at his own request. Vifor Pharma is currently in the recruiting process for the new Chief Financial Officer, to be announced once the successor has been identified. Abbas Hussain, Chief Executive Officer of Vifor Pharma, commented: "On behalf of the company I would like to thank Colin for his valuable contributions and leadership during his tenure at Vifor Pharma. For his next phase of his life I wish him all the best and satisfaction in his future endeavors.” About Vifor Pharma Group Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with sev
Wemade Holds Spectacular Event to Celebrate 100 Days Since Global Launch of MIR430.11.2021 03:34:00 CET | Press release
Wemade’s masterpiece mobile MMORPG ‘MIR4’ will hold a spectacular event starting on November 30th, to celebrate the 100th day of its global release. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005798/en/ Wemade’s masterpiece mobile MMORPG ‘MIR4’ holds a spectacular event starting on November 30th, to celebrate the 100th day of its global release. It will be held for two weeks and special rewards will be given including Divine Dragon’s Blessing, Enhancement Stones, Summoning Tickets, and a special box containing various materials. While hunting monsters on the Mir continent, players can obtain Dragon Fruits. In addition, Wayfarer Travel tickets will be updated that allow for transfers to a different server. New Spirits will also be updated including Bloodtip Drago, a legendary-grade fire element Spirit, and Leocrat Khun, an epic-grade earth element Spirit. To commemorate the release of new spirits, a Spirit Special S
LabGenius Appoints Dr. Gino Van Heeke as Chief Scientific Officer30.11.2021 01:00:00 CET | Press release
LabGenius, the machine learning (ML)-driven protein engineering company, today announced the appointment of Gino Van Heeke Ph.D. as Chief Scientific Officer (CSO). In this role, Gino will leverage his wealth of drug discovery and development experience to direct LabGenius’ scientific strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005436/en/ Dr. Gino Van Heeke Appointed as LabGenius' CSO (Photo: Business Wire) “I’m extremely pleased to welcome Gino to the company as CSO,” said Dr. James Field, Founder and CEO of LabGenius. “Gino is an accomplished scientific leader with an impressive track record of successfully advancing drug candidates into pre-clinical and clinical development.” Gino joins LabGenius from Engitix Therapeutics, where, as CSO, he established a portfolio of projects and initiated the company’s first drug discovery campaign. Before this, Gino was Senior Director, Discovery and Early Development
InVeris Training Solutions Unveils SRCE™ – a Revolutionary, Augmented Reality Training System29.11.2021 20:00:00 CET | Press release
InVeris Training Solutions, the leading provider of integrated live-fire and virtual weapons training systems for military, law enforcement agencies and commercial shooting ranges, today unveils SRCE™ (See, Rehearse, Collectively Experience or "Source"), a groundbreaking, augmented reality-based, untethered weapons training simulator. InVeris Training Solutions provides the most advanced augmented reality technology available in a military and law enforcement training simulator, a feat previously thought to be years away by many in the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005628/en/ SRCE is the only untethered AR training solution on the market—allowing up to 4 participants to train with simulated weapons and tactical gear. (Photo: Business Wire) "Augmented reality delivers the best of the virtual and real worlds in a way that's fully lifelike, seamless, customizable and economical," said InVeris CE
Verimatrix Launches Streamkeeper To Offer Industry’s First Battle-Ready Cybersecurity Solution Engineered to Hunt Down and Take Out Video Piracy29.11.2021 17:45:00 CET | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced the launch of its new Verimatrix StreamkeeperSM solution, a cybersecurity and anti-piracy gamechanger for the media & entertainment industry. Streamkeeper empowers customers to hunt down and take out OTT pirates who steal content such as live sports and premium movie as they are distributed from the source to the endpoint (mobile app/user level). The solution includes Verimatrix's all-new CounterspySM technology -- the autonomous injection of an anti-piracy and app protection security agent that utilizes the company’s proprietary zero code technology which allows customers to add deep, defensive countermeasures, plus monitor their clients without the hassle of a huge integration effort. Integration efforts have also been reduced dramatically, from months to minutes, accompanying numerous operator benefits ranging from a reducti
Introducing ThreatConnect 6.4 - Improving Threat Intelligence Processes and SOC Metrics29.11.2021 17:31:00 CET | Press release
ThreatConnect Inc.®, the leader in enabling a risk led and intelligence-driven security is announcing ThreatConnect 6.4, which introduces new capabilities that allow security operations and cyber threat intelligence (CTI) analysts to get useful context faster during investigations and to better measure team efficiencies. ThreatConnect combines its Threat Intelligence Platform (TIP) and Security Orchestration and Automation platform (SOAR), creating a continuous feedback loop that helps make Intelligence-Driven Operations a reality. This latest product release builds upon the foundation of Intelligence-Driven Operations, empowering the workflow of threat intelligence and security operations teams individually and together. The 6.4 release helps CTI and security operations center (SOC) teams get more context quickly, enabling faster investigations for both. CTI teams are enabled to more easily build and maintain a dynamic threat library, while updated dashboards allow SOC and IR leaders